SEC Form 4 · accession 0001179110-15-012049

ACCELERON PHARMA INC · XLRN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CEO and President · Director

Period of report

Aug 10, 2015

Accepted (ET)

Aug 12, 2015 · 5:55 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001280600

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Aug 10, 2015	M	19,000	$5.08	A	40,584	D
Common Stock^F2	Aug 10, 2015	S	18,500	$28.51	D	22,084	D
Common Stock^F3	Aug 10, 2015	S	500	$29.22	D	21,584	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option to Purchase Common Stock^F4	$5.08	Aug 10, 2015	M	19,000	D	—	Mar 27, 2018	Common Stock	19,000	240,133	D

F1The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.12 to $29.06, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.21 to $29.23, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.